October 2, 2015 Uncategorized

Pacific Biosciences lanza una nueva plataforma de secuenciación basada en su tecnología SMRT

MENLO PARK, California, 2015-10-02 23:23 CEST (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ:PACB, pionera y líder en secuenciación de lecturas largas que utiliza tecnología de una sola molécula en tiempo real (Single Molecule, Real-Time, SMRT(R)), anunció hoy el lanzamiento de una nueva plataforma de secuenciación de ácidos nucleicos.El Sequel(TM)System ofrece un rendimiento y... Read more

October 1, 2015 Life Science Tools

PacBio Sequencing for Human Biomedical Research to be Featured at ASHG Annual Meeting

MENLO PARK, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc., (NASDAQ:PACB) a pioneer and leader in long-read sequencing using Single Molecule, Real-Time (SMRT®) Technology, today announced that its technology will be featured in 36 presentations at next week’s American Society of Human Genetics (ASHG) 2015 annual meeting taking place in Baltimore,... Read more

September 30, 2015 Life Science Tools Product Launch

Pacific Biosciences Launches New Sequencing Platform Based on Its SMRT Technology

Sequel™ System Offers Significantly Higher Throughput, Reducing Project Costs and TimelinesMENLO PARK, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc., (NASDAQ:PACB) a pioneer and leader in long-read sequencing using its Single Molecule, Real-Time (SMRT®) Technology, today announced it has launched a new nucleic acid sequencing platform. The Sequel™ System provides higher... Read more

September 24, 2015 Acad, Gov/Utilities Clinical Research/Diagn.

Precise Diagnosis for Precision Lung Cancer Drug: GE Healthcare’s Clarient Diagnostics Offering FDA approved PD-L1 companion diagnostic for Merck’s Keytruda®

California, USA – 2 October 2015 –  Clarient Diagnostic Services, Inc. a division of GE Healthcare (NYSE:GE) announced it will be offering the FDA approved PD-L1 companion diagnostic which will help identify patients most likely to benefit from Merck’s newly-approved lung cancer drug, Keytruda.   http://www.genewsroom.com/press-releases/precise-diagnosis-precision-lung-cancer-drug-ge-healthcare%E2%80%99s-clarient-diagnostics Read more

September 23, 2015 Uncategorized

GE HEALTHCARE ANNOUNCES $300 MILLION COMMITMENT TO SUPPORT EMERGING MARKET HEALTH

New York City, NY – September 23, 2015 – GE Healthcare, the $18 billion healthcare technology division of GE (NYSE: GE), today announced the creation of a new business unit, Sustainable Healthcare Solutions (SHS), that will develop high-value, low-cost technologies and healthcare delivery solutions across multiple care settings. http://www.genewsroom.com/press-releases/ge-healthcare-announces-300-million-commitment-support-emerging-market-health-281784 Read more

September 10, 2015 Uncategorized

GE Healthcare commends DEA decision that will make DaTscan™ (Ioflupane I 123 Injection) more available to patients who may have Parkinsonism

GE Healthcare (NYSE:GE) is pleased to announce that the US Drug Enforcement Administration (DEA) has removed the compound ioflupane I 123 from the schedules of the Controlled Substance Act, which has resulted in the descheduling of DaTscan™ (Ioflupane I 123 Injection). http://www.genewsroom.com/press-releases/ge-healthcare-commends-dea-decision-will-make-datscan%E2%84%A2-ioflupane-i-123-injection-more Read more

September 7, 2015 M&A, Partnerships

Fujifilm Kyowa Kirin Biologics selects GE’s innovative MabSelect SuRe LX media for biomanufacturing process

Tokyo, Japan and Chalfont St Giles, UK – 7 September 2015 –  GE Healthcare today announced that Fujifilm Kyowa Kirin Biologics has selected GE Healthcare’s innovative MabSelect SuRe™ LX high-affinity chromatography media for the manufacture of monoclonal antibodies. http://www.genewsroom.com/press-releases/fujifilm-kyowa-kirin-biologics-selects-ge%E2%80%99s-innovative-mabselect-sure-lx-media Read more

September 3, 2015 Microscopy Product Launch

JEOL Introduces New Best-in-Class Field Emission SEM

FOR IMMEDIATE RELEASE CONTACT:Patricia Corkum, Marketing Manager978-536-2273 • pcorkum@jeol.com • www.jeolusa.com September 1, 2015, Peabody, MA — JEOL USA has introduced a new entry-level, high-performance Field Emission Scanning Electron Microscope, demonstrated for the first time at M&M 2015 in Portland, Oregon. The new JSM-7200F is a best-in-class FE SEM with ultrahigh spatial resolution of 1.6nm at... Read more

August 31, 2015 Clinical Research/Diagn. Lab Top-10 PR/Corporate

Beckman Coulter Diagnostics Receives 2015 Scientists’ Choice Award for Best New Clinical Laboratory Product

Access Anti-Müllerian Hormone (AMH) Assay Voted Best New Clinical Product of 2014   BREA, CALIF. – (August 31, 2015)  – Beckman Coulter Diagnostics’ automated Access Anti-Müllerian Hormone (AMH) assay* was recently selected as the Best New Clinical Laboratory Product of 2014 for the 2015 Scientists’ Choice Award by members of SelectScience®. The award was presented... Read more